Interested in C-Path updates? Be sure to subscribe at https://lnkd.in/gWTNTi_c For 20 years, C-Path has been providing vital infrastructure to generate a neutral environment for everyone working in drug development to collaborate, not compete. Let's improve lives, together. #CPath #drugdevelopment #neutral #datasharing #globalhealth #collaboration #regulatoryscience
Critical Path Institute (C-Path)
Research Services
Tucson, AZ 8,330 followers
Advancing Drug Development. Improving Lives. Together.
About us
Critical Path Institute (C-Path) is an independent, nonprofit established in 2005 as a public-private partnership, in response to the FDA’s Critical Path Initiative. C-Path’s mission is to lead collaborations that advance better treatments for people worldwide. Globally recognized as a pioneer in accelerating drug development, C-Path has established numerous international consortia, programs and initiatives that currently include more than 1,600 scientists and representatives from government and regulatory agencies, academia, patient organizations, disease foundations and pharmaceutical and biotech companies. With dedicated team members located throughout the world, C-Path’s global headquarters is located in Tucson, Arizona and C-Path’s Europe subsidiary is headquartered in Amsterdam, Netherlands. For more information, visit c-path.org.
- Website
-
http://www.c-path.org/
External link for Critical Path Institute (C-Path)
- Industry
- Research Services
- Company size
- 51-200 employees
- Headquarters
- Tucson, AZ
- Type
- Nonprofit
- Founded
- 2005
- Specialties
- creating collaborations with regulators, patient advocacy groups and the regulated pharmaceutical industry, accelerated development of safer, new medical products, faster, safer, and smarter medical product development, and public private partnership
Locations
-
1840 E River Rd # 100
Tucson, AZ 85718, US
-
Barbara Strozzilaan 201 1083 HN
Amsterdam, NL
Employees at Critical Path Institute (C-Path)
-
Deb Discenza (she/her/hers)
-
Thomas Morel
Global Patient-Centred Outcomes Research & Policy Lead at UCB
-
Huong Huynh Reagan
Regulatory Director | Regulatory endorsements of drug development tools | Cross-functional collaborations | Diverse disease portfolio | Lead people;…
-
Hannah Blau
Data Scientist ∙ ML / NLP Engineer ∙ Listener Extraordinaire ∙ She who does not let stuff fall through the cracks
Updates
-
C-Path’s Mark Drew recently attended the ASSOCIATION OF UNIVERSITY TECHNOLOGY MANAGERS’ (AUTM) Western Region Meeting in Phoenix, where he networked and shared insights about C-Path's Translational Therapeutics Accelerator. This meeting brought together university-based Technology Transfer Offices to discuss strategies for maximizing the impact of their technologies and explore opportunities for collaboration to drive cutting-edge research toward commercialization. Learn more about how TRxA provides funding and support to academic researchers worldwide to advance drug development, here: https://lnkd.in/gueJAXra. If you’d like to be added to our mailing list for updates on our next RFP in January 2025, contact us at [email protected]. #CPath #TRxA #techtransfer #drugdevelopment #datasharing #researchgrants
-
C-Path’s Translational Therapeutics Accelerator Executive Director Maaike Everts, enjoyed connecting in person with her two co-chairs, Mary O'Reilly, PhD from the Flinn Foundation and Raeka Aiyar from the The New York Stem Cell Foundation Research Institute. They led a session during this week’s Health Research Alliance meeting on how to collaborate as non-profits with the federal government. Maaike also served as a panelist for a session titled, ‘Partnerships: Two Sides of the Same Coin,’ speaking to C-Path’s collaborative culture. A few great days of practical information exchange for health research funders! Learn more about how C-Path leads collaborations to accelerate drug development here: https://lnkd.in/gjHpBtyc #CPath #collaboration #FlinnFoundation #NYSCF #drugdevelopment #datasharing #globalhealth #HRA #FDA
-
If you're attending the International Society for Quality of Life Research #ISOQOL Annual Conference this year, be sure to join C-Path's Scottie Kern as he moderates the Digital Health and eCOA Special Interest Group Symposium, discussing the progress and challenges in optimizing patient-reported outcomes in clinical trials. The session, 'Have we truly progressed with optimizing the collection of patient-reported outcomes in clinical trials?,' promises to be a compelling conversation among leaders in the field. This is a must-attend for anyone invested in the future of digital health and electronic clinical outcome assessments. 📅 October 13, 2024 ⏰ 4:30 p.m. 🔗 https://lnkd.in/gqnYsF9Z #CPath #RDCOA #Innovation #RareDiseaseResearch #COA #ISOQOL202
-
Antibiotic resistance is one of the most pressing global health challenges today. At C-Path, we recognize the critical need for long-term investment in antibiotic research and development to safeguard the future of healthcare. That's why, as partners of both ERA4TB and UNITE4TB, we're sharing this important call to action from the AMR Accelerator. This effort stresses the urgent need for sustained funding and collaboration to preserve European capacity in antibiotic R&D. With key infrastructure and expertise already in place, continued support is vital to advancing the development of new treatments for drug-resistant infections. We encourage our community to explore the full commentary in Nature Reviews Drug Discovery, available until October 6, 2024. Let's unite to protect the future of global health. Open Access here: https://lnkd.in/eqGbRqmg #CPath #AMR #AntibioticResistance #GlobalHealth #DrugDevelopment #Partnerships #collaboration
The AMR Accelerator: from individual organizations to efficient antibiotic development partnerships
nature.com
-
▶ New Blog Alert ◀ Accessibility and inclusion at scientific conferences shouldn't be an afterthought. In our latest blog, C-Path's Cole Ayasse, Ph.D., shares their experiences as a wheelchair user navigating barriers at events. Whether you're an organizer, speaker, or attendee, this blog highlights the importance of turning accessibility promises into real action. Let’s push for conferences that truly welcome everyone, regardless of ability. 👉 Read the full blog: https://lnkd.in/ddnw2Yvc. #Accessibility #Inclusion #ScientificConferences #DisabilityAdvocacy #PatientCenteredResearch #DiversityAndInclusion #AccessibleEvents #CPath
-
We're thrilled to announce that C-Path's Lindsey Murray, Executive Director, Rare Disease Clinical Outcome Assessment Consortium, has been selected to participate in the prestigious Cutting Edge Research Plenary at this year’s #ISOQOL Annual Conference. Her presentation, Launch of the Rare Disease Clinical Outcome Assessment Resource, a Tool to Aid in COA-derived Endpoint Selection, was recognized as one of the most innovative submissions. This is a testament to Dr. Murray's dedication to advancing the field of rare disease research. If you're attending, don’t miss her session, where she will share the latest information on C-Path's RD-COA Resource aimed to help streamline COA selection in clinical trials. International Society for Quality of Life Research 📅 October 14, 2024 ⏰ 10:50 a.m. 🔗 https://lnkd.in/gqnYsF9Z #CPath #RDCOA #Innovation #RareDiseaseResearch #COA #ISOQOL2024
-
Please join C-Path in recognizing and thanking members of its Translational Therapeutics Accelerator Scientific Advisory Committee. Its members bring with them broad experience and expertise in drug discovery and development, as well as a shared passion for TRxA’s mission of supporting academic scientists in defining optimal strategies for advancing new, cutting-edge therapeutics from the lab to patient care. The TRxA SAC met this week to discuss several proposals submitted by university-based investigators seeking TRxA funding and support for their projects. Learn more about TRxA at https://lnkd.in/gwwTTgNs. Thank you TRxA SAC members: Lynn Abell, Dianne Bryce, Geert Jan Groeneveld, Elaine H., Karen Lavery, Michael Lawton, Guillermo Morales, PhD, MBA, Chad Souvignier and Jon de Vlieger. Maaike Everts Mark Drew Michelle Morgan #CPath #TRxA #drugdiscovery #translationalTherapeutics #accelerator #drugdevelopment #datasharing
-
This week, C-Path's Diane Stephenson, Executive Director of the Critical Path for Parkinson's Consortium, is at the International Congress of Parkinson's Disease and Movement Disorders. Diane presented a poster on behalf of CPP titled, "Advancing regulatory-endorsed drug development tools in alignment with emerging biology," highlighting key steps to accelerate Parkinson's drug development. Since its launch in 2015, CPP has brought together industry leaders, nonprofits, academic experts, regulatory advisors (FDA, European Medicines Agency, The National Institutes of Health), and people living with Parkinson's, working collaboratively to expedite new treatments for patients. Curious about how CPP is driving progress? Learn more here: https://lnkd.in/gH7vqiW4 #Parkinsons #DrugDevelopment #MovementDisorders #DataSharing #Collaboration #CPath
-
On #LimbGirdleAwarenessDay, we’re proud to announce the launch of C-Path’s new task force dedicated to advancing drug development for limb-girdle muscular dystrophies. Under the Rare Disease Cures Accelerator-Data and Analytics Platform, this collaborative effort unites experts from leading organizations to tackle the unmet medical needs in the LGMD community. This task force includes pivotal members: ML Bio Solutions (BridgeBio), Coalition to Cure Calpain 3, CURE LGMD2I FOUNDATION, Jain Foundation Inc, LGMD2D Foundation, LGMD2i Research Fund and The Speak Foundation. Together, we’re leveraging patient-level data, shared knowledge, and a neutral platform to expedite therapeutic advancements for those affected by LGMDs. As we work toward accelerating meaningful progress, our commitment remains to ensure patient voices and data drive innovation. Read the full details, here: https://lnkd.in/gFiffMB3 Alexandre Bétourné, PhD, PharmD, PMP Heidi Grabenstatter Douglas Sproule Kat Bryant Knudson Ramona Belfiore-Oshan Rachel DeConti Adora Ndu, PharmD, JD Anna Wade Cybele Gouverneur Jean-Pierre Laurent Jennifer Levy Jessica Evans Kelly Brazzo Laura Rufibach Patrick Moeschen #CPath #LimbGirdleMuscularDystrophy #RareDiseaseResearch #DataCollaboration #DrugDevelopment #DataSharing #RDCADAP #PatientVoice #Collaboration